# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Arcutis Biotherapeutics reports its first-quarter financial results after the bell Tuesday.
Arcutis Biotherapeutics (NASDAQ:ARQT) reported quarterly earnings of $0.32 per share which beat the analyst consensus estimate ...
Eight of nine experts expressed feeling "extremely confident" about prescribing ZORYVE foam to patients of diverse skin...
Needham analyst Serge Belanger reiterates Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and maintains $16 price target.
U.S. stocks were lower, with the Dow Jones index falling more than 150 points on Monday.